The total return over the past 12 months is -83.28% vs. +16.94% for the S&P 500. So far it's up -74.40% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (83.21%) | (94.69%) | (93.38%) | N/A | N/A | N/A |
| Total Return CAGR | (83.28%) | (94.70%) | (93.39%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
TransCode Therapeutics, Inc. (RNAZ)
| Year | Start price | End price | RNAZ Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $6.83 | $1.76 | (74.40%) | +14.51% | (88.91%) |
| 2025 | $66.08 | $6.83 | (89.64%) | +17.72% | (107.36%) |
| 2024 | $4,264.96 | $66.08 | (98.45%) | +24.89% | (123.34%) |
| 2023 | $348,237.12 | $4,264.96 | (98.78%) | +26.19% | (124.97%) |
| 2022 | $1,314,297.60 | $348,237.12 | (73.50%) | (18.17%) | (55.33%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
